<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777513</url>
  </required_header>
  <id_info>
    <org_study_id>HEMOFLOW PMS_2020</org_study_id>
    <nct_id>NCT04777513</nct_id>
  </id_info>
  <brief_title>Evaluation of Diagnostic Accuracy, Safety, and Cost-Effectiveness of the Non-Invasive iSIL-FFR (in SILico FFR) Method to Measure the Fractional Flow Reserve in Diagnostics of Chronic Coronary Syndromes Versus the Standard Diagnostic Modalities.</brief_title>
  <official_title>Evaluation of Diagnostic Accuracy, Safety, and Cost-Effectiveness of the Non-Invasive iSIL-FFR (in SILico FFR) Method to Measure the Fractional Flow Reserve in Diagnostics of Chronic Coronary Syndromes Versus the Standard Diagnostic Modalities. A Multicentre Post-marketing Trial of a Class 2a Medical Device, iSIL-FFR (in SILico FFR) - Software for Non-invasive Determination of Haemodynamic Parameters in Coronary Arteries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LifeFlow Sp. z o.o.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GENELYTICA Sp. z o.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LifeFlow Sp. z o.o.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre (5-8 sites), post-marketing, observational trial in 200 patients, whose&#xD;
      standard diagnostic workup for chronic coronary syndromes provided for Invasive Coronary&#xD;
      Angiography (ICA). Medical records of a potential subject of the trial before their enrolment&#xD;
      contain a good quality result of at least 128-slice CCTA performed up to 3 months before the&#xD;
      elective ICA. CCTA should find at least one ≥50% stenosis in at least one big coronary artery&#xD;
      of ≥ 2 mm diameter. At one hour before ICA in the latest the patient should have a resting&#xD;
      Continuous Non-Invasive Blood Pressure (CNBP) taken with a certified device delivered by&#xD;
      LifeFlow. The last criterion before including a patient in the final analysis is at least one&#xD;
      significant (≥50%) stenosis in one or two coronary arteries of ≥ 2 mm diameter visually&#xD;
      confirmed by ICA with a FFR measurement taken in these arteries.&#xD;
&#xD;
      The data collection period will cover time from admission for the elective ICA to discharge&#xD;
      from the hospital (evaluation of possible adverse events related to invasive procedures).&#xD;
&#xD;
      After initial qualification of available data by the attending physician, selected patients&#xD;
      will be asked for a consent to participation in the trial no later than upon admission for&#xD;
      the elective ICA and before CNBP measurement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage 1&#xD;
&#xD;
      After a patient declares their consent, a doctor or another member of the study team trained&#xD;
      by the sponsor will perform procedures in the following order:&#xD;
&#xD;
        -  Define the unique patient ID to be recorded in the CRF with the patient's demographic&#xD;
           data&#xD;
&#xD;
        -  Assess the quality of CCTA imaging data according to guidelines agreed upon with the&#xD;
           sponsor and record the number and location of the significant (≥50%) stenosis sites in&#xD;
           the CRF based on CCTA&#xD;
&#xD;
        -  No later than one hour before ICA starts, perform a physical examination consisting in&#xD;
           instantaneous peripheral blood pressure (systolic and diastolic) resting measurement&#xD;
           performed with a standard sphygmomanometer and Continuous Non-Invasive Blood Pressure&#xD;
           measurement (1-3 min).&#xD;
&#xD;
      Stage 2&#xD;
&#xD;
      After the procedures mentioned above are performed, the patient will undergo elective ICA&#xD;
      with the outcomes, i.e.:&#xD;
&#xD;
        -  video material showing the location of the wire during the FFR measurement,&#xD;
&#xD;
        -  digital pressure signals exported from the FFR measuring device used to determine the&#xD;
           value of the invasive FFR,&#xD;
&#xD;
        -  values of FFR measurements obtained during ICA will be entered after being anonymised in&#xD;
           a dedicated HEMOFLOW PMS_2020 reference database.&#xD;
&#xD;
      Stage 3&#xD;
&#xD;
      Within 48 hours of ICA completion a doctor or another member of the study team trained by the&#xD;
      sponsor:&#xD;
&#xD;
        -  will enter the following data in the iSIL-FFR system:&#xD;
&#xD;
             1. Patient's data, i.e. patient's ID, gender, height, body mass, exercise&#xD;
                tolerability, information on used medications and smoking cigarettes. Optionally,&#xD;
                i.e. if upon admission for ICA a blood test was performed as a part of the standard&#xD;
                diagnostic workup - haematocrit levels and total protein concentration&#xD;
&#xD;
             2. Files containing CCTA imaging data in the DICOM format.&#xD;
&#xD;
             3. Values of instantaneous peripheral blood pressure (systolic and diastolic) resting&#xD;
                measurement performed with a standard sphygmomanometer as well as the digital&#xD;
                signal obtained during the CNBP measurement (1-3 min)&#xD;
&#xD;
        -  Based on the CCTA description or meta data contained in the imaging data the doctor or&#xD;
           another member of the study team will record the following information in the CRF:&#xD;
&#xD;
             1. Radiation dose during CCTA&#xD;
&#xD;
             2. Contrast medium dose during CCTA&#xD;
&#xD;
        -  Will enter the following information in the CRF:&#xD;
&#xD;
             1. Radiation dose during the diagnostic part of ICA&#xD;
&#xD;
             2. Contrast medium dose during the diagnostic part of ICA&#xD;
&#xD;
             3. Number and type of adverse events&#xD;
&#xD;
             4. Duration of the diagnostic workup.&#xD;
&#xD;
      Stage 4&#xD;
&#xD;
      Within 48 hours of entering all the stage 3 data the investigator (a cardiologist) trained by&#xD;
      the sponsor will measure the value of the virtual FFR with the iSIL-FFR system at locations&#xD;
      corresponding to ICA FFR measurements (based on video recording entered in the database&#xD;
      during stage 2)&#xD;
&#xD;
      Based on results obtained from the iSIL-FFR system vs reference data an analysis will be&#xD;
      performed on meeting the primary and secondary end points of the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Days</target_duration>
  <primary_outcome>
    <measure>The evaluation of the increased diagnostic accuracy of the non-invasive iSIL-FFR technology</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluation of the increased diagnostic accuracy (area under ROC curve, AUC) in detection of haemodynamically significant stenoses in coronary arteries with a non-invasive iSIL-FFR technology compared to CCTA in reference to the invasive fractional flow reserve (FFR) testing at the arterial level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The evaluation of diagnostic accuracy of the non-invasive iSIL-FFR technology</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Evaluation of diagnostic accuracy of iSIL-FFR in detection of haemodynamically significant stenoses in coronary arteries (FFR value ≤0.80) compared to CCTA (stenosis ≥ 50%), in reference to the invasive FFR testing at the patient and arterial level, based on parameters like sensitivity, specificity, positive/negative predictive value, accuracy at the patient and arterial level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of safety of the non-invasive iSIL-FFR technology</measure>
    <time_frame>Up to 5 days. The date from admission for the scheduled ICA to discharge from the hospital.</time_frame>
    <description>Evaluation of safety of the non-invasive iSIL-FFR technology (the result of the non-invasive test completes the diagnostic workup for coronary disease) compared to the standard diagnostics in chronic coronary syndromes based on the following parameters:&#xD;
Radiation dose during the diagnostic workup&#xD;
Contrast medium dose in the diagnostic workup&#xD;
Adverse events during the diagnostic workup&#xD;
Duration of the diagnostic workup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of the costs of iSIL-FFR technology</measure>
    <time_frame>Up to 5 days. The date from admission for the scheduled ICA to discharge from the hospital.</time_frame>
    <description>3) Evaluation of the costs of iSIL-FFR in diagnostics of chronic coronary syndromes compared to the standard diagnostic workup (the sum of the costs for individual diagnostic modalities according to the National Health Fund reimbursement prices as well as Procedural Reimbursement Payment Guide)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Stable Ischemic Heart Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Standard of care: FFR, ICA, CCTA</arm_group_label>
    <description>Patients with medical history for ischaemic heart disease will take part in non-invasive determination of haemodynamic parameters in coronary arteries with iSIL-FFR (in SILico FFR) technology.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CCTA (Coronary Computed Tomography Angiography)</intervention_name>
    <description>Per the protocol, patients had a coronary computed tomography angiography within standard of care before the enrollment to the study.</description>
    <arm_group_label>Standard of care: FFR, ICA, CCTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ICA (Invasive Coronary Angiography)</intervention_name>
    <description>Per the protocol, patients will have an Invasive Coronary Angiography within standard of care.</description>
    <arm_group_label>Standard of care: FFR, ICA, CCTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FFR (Fractional Flow Reserve)</intervention_name>
    <description>Per the protocol, patients will have a Fractional Flow Reserve procedure within standard of care.</description>
    <arm_group_label>Standard of care: FFR, ICA, CCTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CNBP measurement</intervention_name>
    <description>Per the protocol, patients will have the measurement of the resting Continuous Non-Invasive Blood Pressure (CNBP). The signal is required for iSIL-FFR technology.</description>
    <arm_group_label>Standard of care: FFR, ICA, CCTA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iSIL-FFR</intervention_name>
    <description>Per the protocol, non-invasive FFR measurements will be perfomed via iSIL-FFR technology for the enrolled patients.</description>
    <arm_group_label>Standard of care: FFR, ICA, CCTA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects enrolled in the trial are patients, who will undergo standard diagnostic workup&#xD;
        for chronic coronary syndromes (including standard procedures according to valid 2019 ESC&#xD;
        guidelines, i.e. medical history for ischaemic heart disease, CCTA, and ICA with FFR as&#xD;
        indicated) as a part of health care services.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18&#xD;
&#xD;
          2. Declaration of informed consent to sharing medical records gathered during the&#xD;
             standard diagnostic workup&#xD;
&#xD;
          3. History of chronic coronary syndromes (CCS)&#xD;
&#xD;
          4. Diagnostic CCTA (good quality test allowing investigation of the entire coronary&#xD;
             artery tree), showing at least one site with stenosis ≥50% of the lumen in a large&#xD;
             coronary artery of ≥ 2 mm diameter, with no prior revascularisation&#xD;
&#xD;
          5. Standard treatment of chronic coronary syndromes with no dosage modification required&#xD;
             within at least 4 weeks before the enrolment&#xD;
&#xD;
          6. Patients with a prior acute coronary syndrome (ACS) or revascularisation would be&#xD;
             found eligible under the following conditions:&#xD;
&#xD;
               -  Over 30 days from the acute coronary syndrome occurrence&#xD;
&#xD;
               -  FFR assessment during ICA may only cover the vessels that were not revascularized&#xD;
                  (both PCI and CABG) and were not the reason of ACS&#xD;
&#xD;
               -  No closed coronary arteries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CCTA-confirmed myocardial bridges causing &gt;50% stenosis of the epicardial vascular&#xD;
             lumen&#xD;
&#xD;
          2. Coronary obstruction confirmed by CCTA or invasive coronarography&#xD;
&#xD;
          3. History of ACS with coronary angioplasty or Coronary Artery Bypass Grafting (CABG)&#xD;
             performed unless point 6 conditions are met&#xD;
&#xD;
          4. Significant haemodynamic abnormalities of the valve or history of surgical correction&#xD;
             of the defect or CABG&#xD;
&#xD;
          5. Second-degree or third-degree atrioventricular block, sinus node dysfunction, QTc &gt;&#xD;
             450 ms or prolonged QTc&#xD;
&#xD;
          6. LVEF ≤ 35% found in an echocardiogram performed within the last 6 months&#xD;
&#xD;
          7. BMI ≥ 35&#xD;
&#xD;
          8. Clinically apparent infection&#xD;
&#xD;
          9. Thrombocytopenia below 100.000/mm3&#xD;
&#xD;
         10. Active neoplastic disease (apart from basal cell carcinoma and carcinoma in situ) and&#xD;
             other conditions, which, in the investigator's opinion significantly affect their life&#xD;
             expectancy&#xD;
&#xD;
         11. Other significant conditions, infections, addictions and psychological or social&#xD;
             factors, which, in the doctor's opinion, may affect patient's ability to participate&#xD;
             in the trial or significantly affect their safety&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cezary Kępka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The National Institute of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wojciech Tarnawski, PhD</last_name>
    <phone>+48 605 111 445</phone>
    <email>wojciech.tarnawski@lifeflow.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnieszka Milewska-Kranc, MA</last_name>
    <phone>+48 509 063 627</phone>
    <email>agnieszka.milewska.kranc@lifeflow.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University Clinical Centre</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kliniczne Centrum Kardiologii</last_name>
      <phone>+48 601 64 99 70</phone>
      <email>kmosakowska@uck.gda.pl</email>
    </contact>
    <investigator>
      <last_name>Miłosz Jaguszewski, Prof., M.D.,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dział ds. badań i pozyskiwania funduszy</last_name>
      <phone>+48 32 359 89 18</phone>
      <email>sekretariat@gcm.pl</email>
    </contact>
    <investigator>
      <last_name>Wojciech Wojakowski, Prof., M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cardinal Stefan Wyszyński National Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dział Badań Klinicznych</last_name>
      <phone>+48 22 343 42 68</phone>
      <email>badaniakliniczne@ikard.pl</email>
    </contact>
    <investigator>
      <last_name>Cezary Kępka, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariusz Kruk, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 4th Military Teaching Hospital</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Badania Kliniczne</last_name>
      <phone>+48 261 660 132</phone>
      <email>naukowy@4wsk.pl</email>
    </contact>
    <investigator>
      <last_name>Bartosz Krakowiak, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Jan Mikulicz-Radecki University Teaching Hospital</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ośrodek Badań Klinicznych</last_name>
      <phone>+48 71 733 27 92</phone>
      <email>badaniakliniczne@usk.wroc.pl</email>
    </contact>
    <investigator>
      <last_name>Krzysztof Reczuch, Prof., M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The T. Marciniak Lower Silesian Specialist Hospital - Center of Emergency Medicine</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Centrum Medycyny Ratunkowej</last_name>
      <phone>+48 71 306 44 19</phone>
      <email>szpital_marciniaka@pro.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Rafał Wyderka, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs317/en/</url>
    <description>WHO Fact sheet N°317 September 2012</description>
  </link>
  <link>
    <url>http://who.int/mediacentre/factsheets/fs310/en/</url>
    <description>WHO Fact sheet N°310 Updated June 2011</description>
  </link>
  <link>
    <url>http://ec.europa.eu/growth/sectors/medical-devices/contacts/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.urpl.gov.pl/pl/wyroby-medyczne/informacje-dotyczące-bezpieczeństwa/formularze</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://academic.oup.com/eurheartj/article/41/3/407/5556137</url>
    <description>2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)</description>
  </link>
  <reference>
    <citation>Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092. Epub 2012 May 3. Erratum in: Eur Heart J. 2012 Sep;33(17):2126.</citation>
    <PMID>22555213</PMID>
  </reference>
  <reference>
    <citation>Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Uva MS, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A; Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC); Europejskie Stowarzyszenie Chirurgii Serca i Klatki Piersiowej (EACTS) do spraw rewaskularyzacji mięśnia sercowego; European Association for Percutaneous Cardiovascular Interventions (EAPCI). [2014 ESC/EACTS Guidelines on myocardial revascularization]. Kardiol Pol. 2014;72(12):1253-379. doi: 10.5603/KP.2014.0224. Polish.</citation>
    <PMID>25524605</PMID>
  </reference>
  <reference>
    <citation>Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29.</citation>
    <PMID>25173339</PMID>
  </reference>
  <reference>
    <citation>Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, van' t Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009 Jan 15;360(3):213-24. doi: 10.1056/NEJMoa0807611.</citation>
    <PMID>19144937</PMID>
  </reference>
  <reference>
    <citation>Lindstaedt M, Fritz MK, Yazar A, Perrey C, Germing A, Grewe PH, Laczkovics AM, Mügge A, Bojara W. Optimizing revascularization strategies in patients with multivessel coronary disease: impact of intracoronary pressure measurements. J Thorac Cardiovasc Surg. 2005 Apr;129(4):897-903.</citation>
    <PMID>15821661</PMID>
  </reference>
  <reference>
    <citation>Reczuch K, Jankowska E, Telichowski A, Porada A, Banasiak W, Ponikowski P. Measurement of fractional flow reserve in patients with multi-vessel coronary artery disease and borderline lesions prevents unnecessary revascularisation procedures. Kardiol Pol. 2004 Apr;60(4):311-19; discussion 320-1. English, Polish.</citation>
    <PMID>15226780</PMID>
  </reference>
  <reference>
    <citation>Toth G, De Bruyne B, Casselman F, De Vroey F, Pyxaras S, Di Serafino L, Van Praet F, Van Mieghem C, Stockman B, Wijns W, Degrieck I, Barbato E. Fractional flow reserve-guided versus angiography-guided coronary artery bypass graft surgery. Circulation. 2013 Sep 24;128(13):1405-11. doi: 10.1161/CIRCULATIONAHA.113.002740. Epub 2013 Aug 28.</citation>
    <PMID>23985788</PMID>
  </reference>
  <reference>
    <citation>De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, Fearon WF; FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27. Erratum in: N Engl J Med. 2012 Nov;367(18):1768. Mobius-Winckler, Sven [corrected to Möbius-Winkler, Sven].</citation>
    <PMID>22924638</PMID>
  </reference>
  <reference>
    <citation>De Bruyne B, Pijls NH, Barbato E, Bartunek J, Bech JW, Wijns W, Heyndrickx GR. Intracoronary and intravenous adenosine 5'-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation. 2003 Apr 15;107(14):1877-83. Epub 2003 Mar 31.</citation>
    <PMID>12668522</PMID>
  </reference>
  <reference>
    <citation>Wongpraparut N, Yalamanchili V, Pasnoori V, Satran A, Chandra M, Masden R, Leesar MA. Thirty-month outcome after fractional flow reserve-guided versus conventional multivessel percutaneous coronary intervention. Am J Cardiol. 2005 Oct 1;96(7):877-84.</citation>
    <PMID>16188509</PMID>
  </reference>
  <reference>
    <citation>Leone AM, Martin-Reyes R, Baptista SB, Amabile N, Raposo L, Franco Pelaez JA, Trani C, Cialdella P, Basile E, Zimbardo G, Burzotta F, Porto I, Aurigemma C, Rebuzzi AG, Faustino M, Niccoli G, Abreu PF, Slama MS, Spagnoli V, Telleria Arrieta M, Amat Santos IJ, de la Torre Hernandez JM, Lopez Palop R, Crea F. The Multi-center Evaluation of the Accuracy of the Contrast MEdium INduced Pd/Pa RaTiO in Predicting FFR (MEMENTO-FFR) Study. EuroIntervention. 2016 Aug 20;12(6):708-15. doi: 10.4244/EIJV12I6A115.</citation>
    <PMID>27542782</PMID>
  </reference>
  <reference>
    <citation>Wu W, Pan DR, Foin N, Pang S, Ye P, Holm N, Ren XM, Luo J, Nanjundappa A, Chen SL. Noninvasive fractional flow reserve derived from coronary computed tomography angiography for identification of ischemic lesions: a systematic review and meta-analysis. Sci Rep. 2016 Jul 5;6:29409. doi: 10.1038/srep29409. Review.</citation>
    <PMID>27377422</PMID>
  </reference>
  <reference>
    <citation>Nakazato R, Park HB, Berman DS, Gransar H, Koo BK, Erglis A, Lin FY, Dunning AM, Budoff MJ, Malpeso J, Leipsic J, Min JK. Noninvasive fractional flow reserve derived from computed tomography angiography for coronary lesions of intermediate stenosis severity: results from the DeFACTO study. Circ Cardiovasc Imaging. 2013 Nov;6(6):881-9. doi: 10.1161/CIRCIMAGING.113.000297. Epub 2013 Sep 30.</citation>
    <PMID>24081777</PMID>
  </reference>
  <reference>
    <citation>Min JK, Leipsic J, Pencina MJ, Berman DS, Koo BK, van Mieghem C, Erglis A, Lin FY, Dunning AM, Apruzzese P, Budoff MJ, Cole JH, Jaffer FA, Leon MB, Malpeso J, Mancini GB, Park SJ, Schwartz RS, Shaw LJ, Mauri L. Diagnostic accuracy of fractional flow reserve from anatomic CT angiography. JAMA. 2012 Sep 26;308(12):1237-45.</citation>
    <PMID>22922562</PMID>
  </reference>
  <reference>
    <citation>Morris PD, van de Vosse FN, Lawford PV, Hose DR, Gunn JP. &quot;Virtual&quot; (Computed) Fractional Flow Reserve: Current Challenges and Limitations. JACC Cardiovasc Interv. 2015 Jul;8(8):1009-1017. doi: 10.1016/j.jcin.2015.04.006. Epub 2015 Jun 24. Review.</citation>
    <PMID>26117471</PMID>
  </reference>
  <reference>
    <citation>Kruk M, Wardziak Ł, Demkow M, Pleban W, Pręgowski J, Dzielińska Z, Witulski M, Witkowski A, Rużyłło W, Kępka C. Workstation-Based Calculation of CTA-Based FFR for Intermediate Stenosis. JACC Cardiovasc Imaging. 2016 Jun;9(6):690-9. doi: 10.1016/j.jcmg.2015.09.019. Epub 2016 Feb 17.</citation>
    <PMID>26897667</PMID>
  </reference>
  <reference>
    <citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep;44(3):837-45.</citation>
    <PMID>3203132</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>Chronic Coronary Syndromes</keyword>
  <keyword>Coronary Artery lesions</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Post-market surveillance</keyword>
  <keyword>Invasive Coronary Angiography</keyword>
  <keyword>Coronary Computed Tomography Angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

